<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861964</url>
  </required_header>
  <id_info>
    <org_study_id>LBIXOS001</org_study_id>
    <nct_id>NCT01861964</nct_id>
  </id_info>
  <brief_title>Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora</brief_title>
  <acronym>XOS</acronym>
  <official_title>Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human and animal studies demonstrate that xylooligosaccharides (XOS) are a highly efficacious
      prebiotic ingredient that delivers benefits at a minimum level of 1.4 g/day (d), which is
      much lower than levels required by fructooligosaccharides (FOS, 5 g/d) or
      galactooligosaccharides (GOS, 8 g/d). XOS promotes gastrointestinal regularity and relieves
      diarrhea and constipation at 0.7 g/d and 1.4 g/d, respectively. Xylooligosaccharides may also
      reduce blood cholesterol and may improve glycemic control, although more data from clinical
      trials are needed to confirm preliminary findings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effects of Xyloologosarcharide (XOS) on colonic bifidobacteria counts in healthy volunteers.</measure>
    <time_frame>10 weeks</time_frame>
    <description>After a 2 weeks of run-in, 30 healthy volunteers were randomly assigned to take 1.4 grams/day of XOS, or 2.8 grams/day or placebo for 8 weeks. The bifidobarteria counts was assessed at screening, baseline, 4, 8 weeks on supplementation of XOS and after 2 week cessation of XOS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of XOS by healthy volunteers</measure>
    <time_frame>10 weeks</time_frame>
    <description>The tolerance of XOS was assessed by questionnaires, adverse event logs with comparison with placebo control group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bifidobacteria</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xylooligosarcharide 2.8g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xylooligosarcharide 2.8grams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xylooligosarcharide 1.4g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (Maltodextrin)</intervention_name>
    <description>Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Maltodextrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Xylooligosarcharide 1.4g</intervention_name>
    <description>8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal</description>
    <arm_group_label>Xylooligosarcharide 1.4g</arm_group_label>
    <other_name>XOS 1.4g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Xylooligosarcharide 2.8g</intervention_name>
    <description>8 capsules (520 mg/capsule) to be taken in the morning and in the evening</description>
    <arm_group_label>Xylooligosarcharide 2.8g</arm_group_label>
    <other_name>XOS 2.8g</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20-50 years of age at screen.

          2. In generally good health

          3. Subjects must read and sign the Institutional Review Board-approved written informed
             consent prior to the initiation of any study specific procedures or enrollment. A
             subject will be excluded for any condition that might compromise the ability to give
             truly informed consent.

        Exclusion Criteria:

          1. Any history of gastrointestinal disease except for appendectomy

          2. No antibiotic, pre- or probiotic or laxative use during the 2 months before the study.

          3. Any subject with a history of diabetes mellitus, or other serious medical condition,
             such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease,
             chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft,
             angioplasty within 6 months prior to screening, current diagnosis of uncontrolled
             hypertension (defined as systolic BP&gt;160mmHg, diastolic BP&gt;95mmHg), active or chronic
             gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid
             disease requiring medication) as indicated by medical history or routine physical
             examination.

          4. Any subject with a screening laboratory value outside of the laboratory normal range
             that is considered clinically significant for study participation by the investigator.

          5. Any subject who currently uses tobacco products.

          6. Any subject who is pregnant or lactating, or becomes pregnant during the study.

          7. Any subject who is unable or unwilling to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Heber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Center for Human Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Center for Human Nutriiton</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Center for Human Nutrition, David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Finegold SM, Li Z, Summanen PH, Downes J, Thames G, Corbett K, Dowd S, Krak M, Heber D. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food Funct. 2014 Mar;5(3):436-45. doi: 10.1039/c3fo60348b.</citation>
    <PMID>24513849</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XOS</keyword>
  <keyword>Xylooligosarcharide</keyword>
  <keyword>Prebiotic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

